Oxford Nanopore seeks valuation of up to £3.8bn
The UK biotech company has chosen to list on its home market rather than go to the Nasdaq in New York, the traditional listing venue for companies in the industry
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts